Modification of ventriculo–arterial coupling by spironolactone in nonischemic dilated cardiomyopathy

Modification of ventriculo–arterial coupling by spironolactone in nonischemic dilated cardiomyopathy

Abstract Aims We sought to clarify the role of ventriculo–arterial (V–A) coupling in the treatment of nonischemic dilated cardiomyopathy (NIDCM) by adding a mineralocorticoid receptor antagonist (MRA) to conventional anti‐failure therapy. Methods and results We employed cardiac magnetic resonance im...

Full description

Bibliographic Details
Main Authors:	Mark A. Lawson, David E. Hansen, Deepak K. Gupta, Susan P. Bell, Douglas W. Adkisson, Ravinder R. Mallugari, Douglas B. Sawyer, Henry Ooi, Marvin W. Kronenberg
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	ESC Heart Failure
Subjects:	Nonischemic cardiomyopathy Ventricular/vascular coupling haemodynamics Magnetic resonance imaging Spironolactone
Online Access:	https://doi.org/10.1002/ehf2.13161

Similar Items

Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy
by: Kenji Okubo, et al.
Published: (2018-08-01)

Role of cardiac MRI in nonischemic cardiomyopathies
by: Senthil Anand, et al.
Published: (2016-05-01)

Current status of the ICD in nonischemic cardiomyopathy
by: Venkatakrishnan Ramakumar, et al.
Published: (2018-01-01)

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy
by: Hyue-Mee Kim, et al.
Published: (2021-04-01)

Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
by: Avnish Tripathi, et al.
Published: (2021-10-01)

Sudden cardiac death in patients with nonischemic cardiomyopathy
by: Brian P. Betensky, et al.
Published: (2014-01-01)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
by: Yanjia Chen, et al.
Published: (2021-09-01)

Sudden cardiac deaths: Role of nonischemic myocardial disorders—Part 1
by: Pradeep Vaideeswar, et al.
Published: (2021-01-01)

Sudden cardiac deaths: Role of nonischemic myocardial disorders—Part II
by: Pradeep Vaideeswar, et al.
Published: (2021-01-01)

Analysis of spironolactone polymorphs in active pharmaceutical ingredients and their effect on tablet dissolution profiles
by: Renata Cunha de Resende, et al.

Spironolactone-Induced Agranulocytosis: A Case Report
by: Shu-Hwa Hsiao, et al.
Published: (2003-11-01)

Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension
by: Dragojević-Simić Viktorija, et al.
Published: (2019-01-01)

Left Ventricular Geometry and Replacement Fibrosis Detected by cMRI Are Associated with Major Adverse Cardiovascular Events in Nonischemic Dilated Cardiomyopathy
by: Bianca Olivia Cojan-Minzat, et al.
Published: (2020-06-01)

Reversible cardiomyopathies
by: Anjaneyulu V Anne
Published: (2018-01-01)

Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design – A two-step, multifactorial, electrophysiology-inclusive approach
by: Konstantinos A. Gatzoulis, et al.
Published: (2021-03-01)

Predictors of In-Hospital Events for Patients with Nonischemic Acute Heart Failure
by: Sudhkar Kanumuri, et al.
Published: (2019-12-01)

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
by: Catherine J. Leader, et al.
Published: (2020-05-01)

Compatibility determination of potassium orotate with spironolactone by high-performance liquid chromatography
by: Ecaterina Mazur, et al.
Published: (2020-10-01)

Spironolactone for Secondary Central Serous Chorioretinopathy: A Challenge-Rechallenge Case
by: Kapil G. Kapoor, et al.
Published: (2017-07-01)

Furosemide and spironolactone doses and hyponatremia in patients with heart failure
by: Ivan Velat, et al.
Published: (2020-08-01)

Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria
by: Ha Yeon Kim, et al.
Published: (2014-12-01)

FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial
by: Alexandra Poinas, et al.
Published: (2020-06-01)

Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
by: Sudeep R. Aryal, et al.
Published: (2021-09-01)

Improving the dissolution properties of spironolactone using liquisolid technique
by: Jafar Akbari, et al.
Published: (2015-09-01)

Interactions Between Aldosterone, Spironolactone and the Cardiotonic Steroids
by: Shidyak, Amjad
Published: (2008)

Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study
by: Azin Ayatollahi, et al.
Published: (2021-09-01)

Diuretic Effect of Prosopis farcta in Comparison with Spironolactone and Hydrochlorothiazide in Hypertensive Rats
by: Zana M.Raoof, et al.
Published: (2020-06-01)

The Effect of Spironolactone on Control of Pulmonary Hypertension in Patients with Obstructive Pulmonary Disease
by: Mohammad Emami, et al.
Published: (2019-01-01)

Caractérisation moléculaire de l’inhibition de la transcription du VIH dépendante de Tat par la spironolactone
by: Lacombe, Benoît
Published: (2016)

Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Furosemide and Spironolactone by Vierordt’s Method in Bulk and Combined Tablet Dosage Form
by: Chavan Rohankumar R., et al.
Published: (2018-07-01)

Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis
by: Valter Viana Andrade-Neto, et al.
Published: (2021-04-01)

Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice
by: Sinawat S, et al.
Published: (2020-06-01)

HPLC – Quality by Design Approach for Simultaneous Detection of Torsemide, Spironolactone and Their Degradant Impurities
by: Bihola Unnati, et al.
Published: (2018-08-01)

NOVEL METHODS OF PATIENTS SELECTION FOR THE CARDIAC RESYNCHRONIZING THERAPY IN NON-ISCHEMIC CARDIOMYOPATHY
by: D. I. Lebedev, et al.
Published: (2015-11-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice)
by: Decio Armanini, et al.
Published: (2020-10-01)

Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis
by: Zeng Q, et al.
Published: (2019-05-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model
by: Mi Young Lee, et al.
Published: (2011-04-01)

Cannot write session to /tmp/vufind_sessions/sess_fqqh0lshlbgdqubd8rhfjatg5v